# Biotech Isn't Expensive, It's Finally Winning - Biotech: The M&A Supercycle - Week of June 29 to July 3, 2026 > Biotech's XBI hit five-year highs, but the sharpest framing of the week was a valuation argument: it would take just 3.7x pharma free cash flow to buy the whole SMID-cap universe, a full turn cheaper than 2020, even as Revolution Medicines walked away from a rumored Merck bid and doubled. Our synthesis of the biotech podcast tape for the week of July 3, 2026. ## Biotech: The M&A Supercycle ### Week of June 29 to July 3, 2026: Biotech Isn't Expensive, It's Finally Winning --- Every buyside meeting in Europe this week apparently opened with the same nervous question: aren't we getting ahead of ourselves? The XBI has ripped from the 130s into the mid-150s in a month, and a decade of getting beaten up has left generalists twitchy. But the sharpest framing of the week wasn't a warning, it was a valuation argument. On the numbers that actually gate a takeout wave, biotech looks *cheaper* than it did at the last top, not richer. The cliff is still the engine. What changed is that the sellers are starting to wonder if they should sell at all. **TL;DR** - **The supercycle now has a valuation leg to stand on.** It would take roughly 3.7x pharma's annual free cash flow to acquire the entire SMID-cap biotech universe in 2026, versus over 5x back in 2020. XBI at five-year highs is being *supported* by pharma cash-flow growth, not floating above it. - **The best biotechs are learning to say no.** Revolution Medicines reportedly turned down a ~50%-premium Merck approach earlier this year at ~$120; the stock is now hitting new highs near $180. The new question on the tape: why sell your Vertex-in-waiting for a one-day pop? - **China, not the FTC, is the real overhang.** Proposed legislation to screen US–China biopharma dealmaking (BINSA) and Most-Favored-Nation pricing dominated BIO. Deals are already dying over it. Domestic antitrust barely rated a mention. ## What's new **The metric that reframed the whole rally.** On Biotech Hangout's ["Episode 187"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjOr-2FbHRshMd3ZsOVxIrY4pFsx1x81WI1a4G7Ga81LQ-2FI9h4P0-2Fvrnh-2BiXnQvlr4MpYJGG1MgyoBFHbJ4hy4aoOFJacVT7yZDit-2B1viK7WdQg-3D-3De6Vi_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXliJyL5yyrRPCyh0RV-2Bg1DzTcc2k61aC3FdAMDWvgN78hb7o-2BxvAqySFW2HL7K-2Bam5Mv74qZY39079gR2XpqVJ0YDct6Pz4dJYsuY0w6-2FkcKwkDjoOk5kD-2B8gITZKWOT4OR2-2F4q16Sb7EM93rWZD77KpLrgMMb3syrI63SgqA4jg-3D-3D) (June 26), investor Tess Cameron laid out the gauge her shop anchors to: how many years of large-cap pharma free cash flow it would take to buy every SMID-cap biotech. "2020 was really high… over five years." Today? "A bit under four," she pegged 2025 at ~3.5x and 2026 at 3.7x. Her read: "the growth that we're seeing in biotech is certainly supported by the growth that we are seeing in pharma-free cash flows." Translation for anyone calling a top: on the one ratio that governs pharma's ability to hoover up the sector, we're a full turn cheaper than the last euphoric peak. (This is buyside opinion, not gospel, but it's a genuinely useful frame.) **A seller with the nerve to walk.** Same episode, the anecdote that's quietly rewiring how boards think. Eric Schmidt: Revolution Medicines was at 80, "there was rumor that Merck was going to buy them for maybe a whopping 50% premium around 120. And something happened… there was no deal. And today, what, the stock's hitting new highs at 180." Cameron's gloss: investors who came into RevMed's latest raise "are looking at a future… Vertex." The debate this opens is real: with biotech finally able to build profitable, diversified companies, selling your best asset to pharma for a 2x overnight may forfeit far more. As Schmidt put it, keeping that cash-flow power inside the XBI "would be incredibly powerful for the entire sector, probably dwarfing what one could accomplish through M&A." **AbbVie's Apogee bet gets its strategic spine.** Last week the ~$11B Apogee deal was a headline; this week we got the logic. Per Citeline's ["Scrip's Five Must-Know Things"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg2-2Bm11bwc0KU-2F1n-2FVaedNkSThGgC2Mt9cVyQVoaouRrzRc66PwNhmYQXr50V7JqIQhU1TPSH4cjVLhw-2F1I5DFsgc9WK9psVv-2B2FY29-2Fa7Zng-3D-3DaPBz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXliJyL5yyrRPCyh0RV-2Bg1DzTcc2k61aC3FdAMDWvgN78-2Fwv1Q2YMoo9jr98YJ6BRFc2gzLmehC2paYS2epCDn6Eboj-2B9lUyc4B8E-2BzocDin1kHSgT4Vi5hwzVkIXI8DgwhQvwCeg2BugaV8qgei9N9MD3nxjmXiiZ40h18s-2BE7Eg-3D-3D) (June 29), AbbVie is funding the buy with roughly $11 billion of debt, and CEO Robert Michael, an operator, called lead candidate Zumilokibat a "pipeline-in-a-product" asset that should deliver "mega-blockbuster revenue." The tell is timing: the IL-13 antibody could launch in 2030, just ahead of Dupixent's ~2031 exclusivity wall, with dosing as sparse as four times a year. William Blair's Matt Phipps flagged efficacy "at least as good as" Dupixent and Lilly's Ebglyss. On Biotech Hangout, Cameron nailed why AbbVie paid up: "order of entry really matters… strategics are willing to pay a lot for that." This is the post-Humira franchise being defended a decade in advance. **The 2032 map tells you where the money will be.** Citeline relayed Evaluate's 2026 World Preview: global drug sales cross **$2 trillion by 2032**, five drugs each clear $20B, and the top 20 drugs eat nearly a fifth of all sales. Lilly's tirzepatide tops $70B ("the biggest drug ever"), and Lilly alone sells ~$137B, about 60% more than second-place AbbVie, whose Skyrizi lands as the **#2 drug on earth at over $33 billion**. Dupixent stays above $20B; Novo's Ozempic and Wegovy fall out of the top 10. The through-line: biologics and huge-population franchises are where the durable revenue lives, which is exactly what the M&A is chasing. **Sangamo goes out the back door, and Lilly and Astellas are waiting.** A reminder that the cycle has losers too. Per Citeline, delisted Sangamo filed Chapter 11 and is selling assets to two big-pharma stalking horses: Lilly takes its delivery platforms plus a prion program for $50 million and assumed liabilities; Astellas takes its Fabry gene therapy for $25 million up front and $25 million in milestones. The gene-therapy space "has been tough," but Lilly and Astellas buying the scraps says they still believe in the modality. ## The debate The tape leaned bullish again, but this week the bull case got *deeper*, not just louder. **The supercycle bull case** now rests on three legs: cash-flow-relative valuation (Cameron's 3.7x vs 5x+), a still-open capital-markets window (busiest biotech IPO year since 2021, the largest-ever biotech follow-on and IPO both priced this year, per J.P. Morgan's bankers on ["Dealmaking in healthcare"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjDiJYRckEiX1HdItt1L-2BebS7-2FOwg31bltDQ7gzRgjOtaqB92cj1TwrNHOb-2FUk09I5uHC3bP7K6vFGmvq15LGolA-3D-3DMt9L_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXliJyL5yyrRPCyh0RV-2Bg1DzTcc2k61aC3FdAMDWvgN7ykwF3X04TT5PCaiM9Gbv9nT-2BvlZK-2B2hYVjz0oCPRraBMl2TzAr0-2Bc1lYhhC99sV7A5bef-2FAYsnC50jMHtdIONZPF8EvKDkVvdbdEiTaUxsHCNDU0gJrJnExSVjTvSU13w-3D-3D), June 26), and a normalizing FDA ([BioSpace, July 1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjoL2aDAbvkwLvZZsxwQpSu-2BlslDl4ULscpL7cZQgYWSLcGJ8N52b3RTM8t6CD-2FLsUmm8eP2RTaJ9PkBUdleLpzgYAr0kzTdxUEDPtf9-2BxBRg-3D-3Dtz-6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXliJyL5yyrRPCyh0RV-2Bg1DzTcc2k61aC3FdAMDWvgN70nIN9idaOwyZKJiAAi66uGy6qL2YzvAULWikR-2BmygKm-2BBmkRTuTcPn9VXLE9bldxGmNWWDuLPwEHpRJnNCYP0RN7x-2Bb0EMxjbMmRK07yaGpGHtpJnMAw6-2B-2F5wY5qd5TWg-3D-3D)). Jerry Lee's earlier line still frames the demand side: large caps are doing "almost a deal every week," and their investors are "relatively price insensitive… because the durability of these LOEs is just so large." **The bear/caution case,** to the extent it was voiced, was almost entirely reflexive rather than analytical, the "PTSD" nervousness Schmidt described, plus a new worry that biotech is now correlated to an AI bubble it wasn't exposed to before. As Sam Fazeli of Bloomberg Intelligence put it, the fear isn't just where the XBI goes, "but also… what happens if this AI bubble bursts." Worth noting a genuine skeptic's data point from the same room: Schmidt ran a regression of XBI returns against M&A deal value over five-plus years and found "almost no correlation… an R-squared of 0.2." So the reflexive "M&A drives the XBI" story is shakier than the bulls imply: the dollars flow in, but they don't mechanically move the index. > "It feels like… almost a perfect storm in terms of the fundamentals coming together here," said Eric Schmidt, on why the XBI rally may not be as frothy as it looks. ## The names in play - **RVMD**: the exhibit of the week. Walked away from a rumored ~50%-premium Merck bid; now at new highs near $180 and being underwritten as a future Vertex. Buyside conviction that independence beats a takeout. - **ABBV / APGE**: the deal that keeps giving context. ~$11B in debt for a "pipeline-in-a-product" IL-13 antibody, launching 2030 to front-run the Dupixent cliff. Operator conviction, premium price. - **LLY**: the acquirer with no cliff problem and the widest wallet: nine deals in H1, ~$25–30B spent, plus stalking-horse bids for Sangamo. Evaluate sees it at ~$137B of sales by 2032. - **MRK**: the buyer that keeps getting turned down (RevMed) while its own 2028 Keytruda cliff looms. Not voiced in detail this week, but the pressure is the subtext of every "who's next" conversation. ## Read-throughs - **Bankers are the cleanest beneficiaries.** J.P. Morgan's team ticked off the largest cross-border deal of the year (Sun Pharma/Organon), the largest-ever European biotech private sell-side (Tubulus to Gilead), record follow-ons and the busiest IPO year since 2021. A deal-a-week pipeline plus a wide-open ECM window is a direct feed to advisory and underwriting revenue. - **China is a two-way read-through.** 2025 saw roughly 150 China-to-West BD deals, but only about $7B in real upfront cash against $135B of headline "biobucks." The assets keep flowing in (Apogee's data, spin-outs reversing into US shells), even as Washington debates screening them. - **Biosimilars and CROs**: quiet. No named biosimilar maker moved a thesis this week; the biosimilar angle showed up only obliquely, in the order-of-entry math behind AbbVie racing to launch before Dupixent's cliff. CROs didn't rate a mention. ## What changed Last week the story was AbbVie/Apogee resetting the year's high-water mark and a banker describing the deal pace as *weekly*, with the skeptics gone missing. This week the bulls did something more durable than press their advantage: they built a floor under the thesis. The supercycle stopped being a momentum call ("deals every week") and became a valuation call ("biotech is a full turn of pharma FCF cheaper than 2020"). And the plot twist: the pressure is inverting. It's no longer just "which pharma is desperate enough to overpay," it's "which biotech is good enough to refuse." RevMed said no and doubled. That's a new kind of leverage for the sell side of the table, and it's the development most worth tracking into the back half. Meanwhile the regulatory fear moved off the FTC (which still isn't part of the pharma conversation) and onto China (BINSA/COINs Act screening) and Most-Favored-Nation pricing, which is already reshaping how companies structure ex-US rights. That's the overhang to watch, not domestic antitrust.